Edward Arrowsmith

Affiliations

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, Tennessee, USA.

Publications (2)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

Journal for immunotherapy of cancer

Avec: Scott S Tykodi , Lucio N Gordan , Robert S Alter , Michael R Harrison , Ivor Percent , Rakesh Singal , Peter Van Veldhuizen , Daniel J George , Thomas Hutson , Joshua Zhang , Jesus Zoco , Jennifer L Johansen , Arash Rezazadeh Kalebasty

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

Cancer immunology, immunotherapy : CII

Avec: Gerald S Falchook , James Reeves , Sunil Gandhi , David R Spigel , Daniel J George , Janet Karlix , Gayle Pouliot , Maureen M Hattersley , Eric T Gangl , Gareth D James , Jeff Thompson , Deanna L Russell , Bhavickumar Patel , Rakesh Kumar , Emerson Lim

Réseau de co-auteurs

Daniel J George 2 collaborations

Scott S Tykodi 1 collaboration

Lucio N Gordan 1 collaboration

Robert S Alter 1 collaboration

Michael R Harrison 1 collaboration

Ivor Percent 1 collaboration

Rakesh Singal 1 collaboration

Peter Van Veldhuizen 1 collaboration

Thomas Hutson 1 collaboration

Joshua Zhang 1 collaboration

Jesus Zoco 1 collaboration

Jennifer L Johansen 1 collaboration

Arash Rezazadeh Kalebasty 1 collaboration

Gerald S Falchook 1 collaboration

James Reeves 1 collaboration

Sunil Gandhi 1 collaboration

David R Spigel 1 collaboration

Janet Karlix 1 collaboration

Gayle Pouliot 1 collaboration

Maureen M Hattersley 1 collaboration

Eric T Gangl 1 collaboration

Gareth D James 1 collaboration

Jeff Thompson 1 collaboration

Deanna L Russell 1 collaboration

Bhavickumar Patel 1 collaboration

Rakesh Kumar 1 collaboration

Emerson Lim 1 collaboration